title: Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes.
authors.affiliation: Oncology Clinic, Mustafa Kemal University Medical Faculty Antakya Hatay Turkey E-mail : drtanersu@yahoo.com.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Sezer
authors.forename: Ahmet Taner
authors.initials: AT
authors.lastname: Sumbul
authors.forename: Huseyin
authors.initials: H
authors.lastname: Abali
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents